Emerald Horizon Prepares for Vienna Stock Exchange Listing
Austrian deep-tech firm Emerald Horizon AG, a company focused on the development of thorium-based slight modular reactor (SMR) technology, has announced plans for an initial public offering (IPO) on the Vienna Stock Exchange. The company is positioning itself as a significant player in the evolving landscape of modular nuclear energy, with a strategy that emphasizes both technological innovation and a commitment to European capital markets.
Strategic Market Positioning
Emerald Horizon is targeting a valuation of approximately 790 million euros for its upcoming IPO. In a move that signals a preference for European markets, the company has chosen to list via Xetra in Vienna, with an indicative start date set for June 10, 2026. This decision stands in contrast to the trend of many European technology firms seeking listings in the United States.

To support the market debut, the company plans to utilize three market makers, supplemented by research coverage and an international marketing program. The company aims for a daily trading volume exceeding 500,000 euros, with an expected free float market value of approximately 200 million euros.
Technology and Global Ambitions
The core of Emerald Horizon’s business model is its development of next-generation SMR technology, branded as “SMR X.” These systems are designed to provide scalable, low-CO2 baseload energy, integrated with energy storage infrastructure. Unlike conventional large-scale nuclear power plants, SMRs are engineered to be more compact and modular, allowing for easier manufacturing and deployment.
While the current focus is on the Vienna listing, the company maintains a broader global strategy. A US subsidiary is already active, exploring opportunities within the North American energy market. Management has indicated that a secondary listing in the United States could be considered in the future to broaden the company’s access to international investors.
Key Takeaways
- IPO Timeline: Emerald Horizon targets a June 10, 2026, listing on the Vienna Stock Exchange via Xetra.
- Valuation Goals: The company is aiming for an IPO valuation of 790 million euros, with a 200 million euro expected free float.
- Core Technology: The firm specializes in thorium-based Small Modular Reactors (SMRs) designed for baseload power generation.
- Market Strategy: By listing in Vienna, the company aims to support European innovation, though it maintains a US subsidiary to facilitate potential future international expansion.
The Role of SMRs in Future Energy Policy
Small Modular Reactors are currently a focal point of energy policy in both the European Union and the United States. As nations seek to balance the need for reliable baseload power with ambitious carbon-reduction targets, SMRs offer a potential solution that combines the energy density of nuclear power with the flexibility of modular infrastructure. Emerald Horizon’s focus on thorium-based designs places it in a specialized niche of this sector, as thorium is often cited for its safety and abundance compared to traditional nuclear fuels.

The final implementation of the IPO remains subject to standard regulatory approvals. As the company moves toward its June date, investors and industry observers will be watching to see how the market responds to this entry from the deep-tech energy sector.
Frequently Asked Questions
What is an SMR?
An SMR, or Small Modular Reactor, is a nuclear power plant that is smaller in size and power capacity than traditional reactors. They are designed to be manufactured in factories and transported to sites, making them more scalable and potentially more cost-effective to deploy.
Why is Emerald Horizon listing in Vienna?
The company has stated that listing in Vienna is a deliberate strategic choice to support the European tech ecosystem, rather than following the common trend of European firms opting for US-based IPOs.
Is the IPO date final?
The date of June 10, 2026, is currently an indicative target. The final execution of the IPO is dependent upon receiving the necessary regulatory approvals.